PENTASA Drug Patent Profile
✉ Email this page to a colleague
When do Pentasa patents expire, and when can generic versions of Pentasa launch?
Pentasa is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in PENTASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pentasa
A generic version of PENTASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PENTASA?
- What are the global sales for PENTASA?
- What is Average Wholesale Price for PENTASA?
Summary for PENTASA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 181 |
Clinical Trials: | 25 |
Patent Applications: | 3,295 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for PENTASA |
Drug Sales Revenues: | Drug sales revenues for PENTASA |
What excipients (inactive ingredients) are in PENTASA? | PENTASA excipients list |
DailyMed Link: | PENTASA at DailyMed |
![PENTASA drug patent expirations Drug patent expirations by year for PENTASA](/p/graph/s/t/PENTASA-patent-expirations.png)
![Drug Prices for PENTASA](/p/graph/drug-price/PENTASA.png)
![Drug Sales Revenue Trends for PENTASA](/p/graph/drug-sales-revenues/PENTASA.png)
Recent Clinical Trials for PENTASA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine | N/A |
Bogomolets National Medical University | N/A |
AIDS Healthcare Foundation | Phase 1/Phase 2 |
Pharmacology for PENTASA
Drug Class | Aminosalicylate |
US Patents and Regulatory Information for PENTASA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-002 | Jul 8, 2004 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PENTASA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
Takeda Pharms Usa | PENTASA | mesalamine | CAPSULE, EXTENDED RELEASE;ORAL | 020049-001 | May 10, 1993 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PENTASA
See the table below for patents covering PENTASA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 8102671 | ⤷ Sign Up | |
Japan | S57500432 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |